Trial reportJournal of clinical hypertension (Greenwich, Conn.)2016
Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06098300 (Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study
Who cites it
10 citing papers in PubMed.
- Impact of hypertension on cerebral microvascular structure in CPAP-treated obstructive sleep apnoea patients: a diffusion magnetic resonance imaging study.Neuroradiology · 2019Trial
- Early retinal microvascular abnormalities in patients with chronic kidney disease.Microcirculation (New York, N.Y. : 1994) · 2019Trial
- Trial
- The effect of systemic factors on retinal blood flow in patients with carotid stenosis: an optical coherence tomography angiography study.GeroScience · 2022Article
- Impact of Arterial Hypertension on the Eye: A Review of the Pathogenesis, Diagnostic Methods, and Treatment of Hypertensive Retinopathy.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- The characteristics of choriocapillaris flow void in the unilateral polypoidal choroidal vasculopathy fellow eyes.Scientific reports · 2021Article
- Systemic hypertension associated retinal microvascular changes can be detected with optical coherence tomography angiography.Scientific reports · 2020Article
- Impact of hypertension on retinal capillary microvasculature using optical coherence tomographic angiography.Journal of hypertension · 2019Observational
- Early vascular parameters in the micro- and macrocirculation in type 2 diabetes.Cardiovascular diabetology · 2018Article
- Retinal capillary rarefaction in patients with untreated mild-moderate hypertension.BMC cardiovascular disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decreased capillary density influences vascular resistance and perfusion. The authors aimed to investigate the influence of the renin-angiotensin receptor blocker valsartan on retinal capillary rarefaction in hypertensive patients. Retinal vascular parameters were measured noninvasively and in vivo by scanning laser Doppler flowmetry before and after 4 weeks of treatment with valsartan in 95 patients with hypertension stage 1 or 2 and compared with 55 healthy individuals. Retinal capillary rarefaction was determined with the parameters intercapillary distance (ICD) and capillary area (CapA). In hypertensive patients, ICD decreased (23.4±5.5 μm vs 21.5±5.6 μm, P<.001) and CapA increased (1564±621 vs 1776±795, P=.001) after valsartan treatment compared with baseline. Compared with healthy normotensive controls (ICD 20.2±4.2 μm, CapA 1821±652), untreated hypertensive patients showed greater ICD (P<.001) and smaller CapA (P=.019), whereas treated hypertensive patients showed no difference in ICD (P=.126) and CapA (P=.728). Therapy with valsartan for 4 weeks diminished capillary rarefaction in hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.